What is the price of Intellipharmaceutics International Inc. (IPCIF)

The price of Intellipharmaceutics International Inc. (IPCIF) is $0.15

What is the market cap of Intellipharmaceutics International Inc. (IPCIF)

The market cap of Intellipharmaceutics International Inc. (IPCIF) is $4.96M

Intellipharmaceutics International Inc. (IPCIF) Earnings

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Year	Earnings	Change
2026 (TTM)	$-3.17M	9.75%
2022	$-2.89M	0.00%
2021	$-2.89M	-45.11%
2020	$-5.26M	56.62%
2019	$-3.36M	-75.57%
2018	$-13.75M	55.21%
2017	$-8.86M	-12.68%
2016	$-10.14M	36.40%
2015	$-7.44M	92.83%
2014	$-3.86M	-66.45%
2013	$-11.50M	135.54%
2012	$-4.88M	95.22%
2011	$-2.50M	-56.34%
2010	$-5.73M	-55.76%
2008	$-12.94M	-56.95%
2007	$-30.07M	-49.08%
2006	$-59.05M	-25.61%
2005	$-79.37M	13.77%
2004	$-69.77M	173.92%
2003	$-25.47M	104.32%
2002	$-12.47M	36.27%
2001	$-9.15M	41.00%
2000	$-6.49M	0.00%
1999	0.00	0.00%

Year

Earnings

Change

2026 (TTM)

$-3.17M

9.75%

2022

$-2.89M

0.00%

2021

$-2.89M

-45.11%

2020

$-5.26M

56.62%

2019

$-3.36M

-75.57%

2018

$-13.75M

55.21%

2017

$-8.86M

-12.68%

2016

$-10.14M

36.40%

2015

$-7.44M

92.83%

2014

$-3.86M

-66.45%

2013

$-11.50M

135.54%

2012

$-4.88M

95.22%

2011

$-2.50M

-56.34%

2010

$-5.73M

-55.76%

2008

$-12.94M

-56.95%

2007

$-30.07M

-49.08%

2006

$-59.05M

-25.61%

2005

$-79.37M

13.77%

2004

$-69.77M

173.92%

2003

$-25.47M

104.32%

2002

$-12.47M

36.27%

2001

$-9.15M

41.00%

2000

$-6.49M

0.00%

1999

0.00

0.00%

Company	Earnings	Earnings Difference	Country
Novo Nordisk A/S NVO.US	$20.46B	-645,746.69%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	$4.64B	-146,643.73%	US
Regeneron Pharmaceuticals, Inc. REGN.US	$5.23B	-165,185.78%	US
UCB SA UCB.BR	$2.14B	-67,567.64%	BE
Argenx SE ARGX.US	$1.45B	-45,897.45%	NL

Company

Earnings

Earnings Difference

Country